China’s National Medical Products Administration (NMPA) announced on 21 October the work plan for a pilot program to allow the non-end-to-end manufacturing of a broad range of biologic pharmaceuticals.
Its scope includes innovative drugs, those with urgent clinical needs and NMPA-designated products such as multivalent vaccines, antibodies, antibody-drug conjugates (ADCs), GLP-1 agonists and insulin.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?